WHO recommends second malaria vax, it will be rolled out next year

GENEVA: The World Health Organization recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes.
”Almost exactly two years ago, WHO recommended the broad use of the world’s first malaria vaccine called RTS,S,” WHO chief Tedros Adhanom Ghebreyesus said. ”Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease.” R21/Matrix-M, developed by Britain’s University of Oxford, will become available to countries by mid-2024, Tedros said, adding that doses would cost between $2 and $4.
R21/Matrix-M is mass manufactured by Serum Institute of India and uses Novavax’s Matrix M adjuvant. Adar Poonawalla, CEO of SII, said it had already produced more than 20 million doses in anticipation of WHO’s recommendation. ”We will ramp it up as per what the demand requirements are,” he said. ”We hope that by the end of 2024, there will be zero mismatch of demand and supply, with our supply coming into the system.”

Ei kommentteja, oletko sinä ensimmäinen?


Sähköpostiosoitettasi ei julkaista.